Advertisement

Topics

Chugai Pharma USA, Inc. Company Profile

11:32 EST 23rd January 2019 | BioPortfolio


News Articles [489 Associated News Articles listed on BioPortfolio]

Results of Global Phase III Study with Chugai's HEMLIBRA® for Hemophilia A Without Inhibitors ...

For MediaChugai Pharmaceutical Co., Ltd.Media Relations Group, Corporate Communications Dept.,Tomoko ShimizuTel: +81-3-3273-0881E-mail: pr@chugai-pharm.co.jp***For US mediaChugai ...

Lilly Licenses Chugai Pharma's Oral Diabetes Drug for $50 Million Upfront

Eli Lilly just signed a license deal with Tokyo’s Chugai Pharmaceutical Co. for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist. It is Phase 1-ready being evaluated for type 2 diabetes.

Announcement of Business Expansion of Chugai Pharmabody Research Pte. Ltd., Chugai’s Research Subsidiary

TOKYO–(BUSINESS WIRE)–#antibody—Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that it has decided to expand the business of Chugai Pharmabody Research Pte. Ltd. (herei...

Roche-Tochter Chugai erhält für Satralizumab FDA-Status Therapiedurchbruch

Basel/Tokio (awp) - Die japanische Roche-Tochter Chugai hat mit den Daten für ihren Produktkandidaten Satralizumab auch die US-Gesundheitsbehörde FDA überzeugt. Wie Chugai ebenfalls am Mittwoch mit...

#news #biotech Eli Lilly nets an early-stage GLP-1 diabetes drug from Chugai for $50M

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Eli Lilly nets an early-stage GLP-1 diabetes drug from Chugai for $50M .Eli L...

Chugai Pharmaceutical to expand Singaporean research subsidiary

Japan-based Chugai Pharmaceutical has revealed plans to expand its research subsidiary in Singapore, Chugai Pharmabody Research (CPR), in order to...Read More... The post Chugai Pharmaceutical to expa...

Satralizumab von Chugai erhält von FDA den Status "Breakthrough Therapy" für Neuromyelitis optica und Neuromyelitis-optica-Spektrum-Erkrankungen

Siebte Status-Zuerkennung für Medikament von Chugai Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) gab bekannt, dass die US-amerikanische Zulassungsbehörde FDA den Status "Breakthrough Therapy" (Du.....

Roche-Tochter Chugai geht Lizenzvereinbarung mit Roche für Entrectinib ein

Wie der japanische Pharmakonzern am Dienstag mitteilt, erhält Chugai im Zuge der Vereinbarung die exklusiven Rechte, den Kandidaten in Japan zu entwickeln und zu vermarkten. Dafür werde man eine ei....

Drugs and Medications [61 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [Mayne Pharma Inc]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Mayne Pharma Inc]

Fluoride Chewable Tablets 1 mg

Urea [Mayne Pharma Inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [Aventis Pharma Ltd.]

NA

Ribavirin [Aurobindo Pharma Limited]

NA

PubMed Articles [26 Associated PubMed Articles listed on BioPortfolio]

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Clinical trials go virtual, big pharma dives in.

Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals.

Research on effectiveness of DAA is limited. Existing researches explore impact of DAA only on relationship between drug manufacturers and consumers. However, in reality, pharma marketing revolves aro...

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ...

CVS and the $100,000 QALY.

The PBM unit of the health giant CVS decided that any new drug exceeding $100,000 per quality-adjusted life year (QALY) may be excluded from the formularies that are maintained by its clients. Patient...

Clinical Trials [88 Associated Clinical Trials listed on BioPortfolio]

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

OK432 (Picibanil) in the Treatment of Lymphatic Malformations

Standard of care for Lymphatic Malformations has been surgical excision. We have been using OK432/Picibanil (generously supplied by Chugai Pharmaceuticals in Japan) since 1992 with great s...

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

Companies [798 Associated Companies listed on BioPortfolio]

Chugai Pharma Europe Limited

European headquarters of Chugai Pharmaceutical Co. Ltd. and Chugai Pharma UK Ltd.

Chugai Pharma Europe Ltd

Chugai Pharmaceutical Co., Ltd is headquartered in Tokyo, Japan. In its home market, Chugai is a household name, with a broad-ranging product portfolio encompassing highly specialised therapeutic anti...

Chugai Pharma USA, Inc.

Chugai Pharmaceutical Co., Ltd

Chugai Pharmaceutical Co., Ltd. places tremendous importance on the safekeeping of personal information obtained from customers using our website (information that is personally identifiable such as y...

Chugai Pharmaceutical Co., Ltd.

More Information about "Chugai Pharma USA, Inc." on BioPortfolio

We have published hundreds of Chugai Pharma USA, Inc. news stories on BioPortfolio along with dozens of Chugai Pharma USA, Inc. Clinical Trials and PubMed Articles about Chugai Pharma USA, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chugai Pharma USA, Inc. Companies in our database. You can also find out about relevant Chugai Pharma USA, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record